# Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT06281886** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 170 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Efficacy
- Toxicity

## Interventions

- **DRUG:** Induction Immunotherapy-Toripalimab
- **DRUG:** Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin
- **RADIATION:** Radiotherapy
- **DRUG:** Apatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06281886
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06281886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06281886, "Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06281886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*